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Summary.-An enzyme-linked immunosorbent assay (ELISA) was developed in
which a tumour-specific component of human squamous-cell carcinoma of the lung
could be readily detected using an absorbed rabbit antiserum. This antiserum did
not react with equivalent preparations made from pooled normal lung tissue. In a
study using the coded sera from normal individuals and preoperative patients
subsequently shown to have Stage I bronchogenic carcinoma of various histo-
logical types, we found that the patients' sera effectively inhibited the reaction
between the rabbit antiserum and the partially purified tumour antigen, whereas the
serum from normal individuals did not.
OVER THE PAST DECADE, a number of
investigators have reported the presence
of tumour-associated antigens (HTAA)
in various types of human bronchogenic
carcinoma (Yachi et al., 1968; Mohr et al.,
1974; Sega et al., 1974; Braatz et al.,
1978). In these publications, the observa-
tions have indicated that there are indeed
HTAA associated with thistype oftumour,
and that these HTAA may well cross-react
for at least a given histological tumour
type. The experimental approach in these
studies has essentially involved immuniza-
tion of experimental animals with solubil-
ized extracts of the tumour in question,
followed by extensive absorption of the
resulting antiserum with normal tissue
components, and detection of HTAA by
immunodiffusion studies with either
tumour or normal tissue extracts. Using a
similar approach, investigators in this
laboratory came up with observations
analogous to the above-mentioned studies
(Watson et al., 1975).
More recently, we used a somewhat dif-
ferent protocol to produce xenoantiserum
to HTAA. This approach involved the
exploitation of a principle described and
discussed some years ago by Moller (1969)
in which the immune response to a par-
ticular antigen can be effectively repressed
by specific passive immunization of the
recipient animal at the time of immuniza-
tion. By immunizing rabbits with a
mixture of rabbit antibody raised against
normal human lung extract and extracts
of human squamous-cell carcinoma, we
were able to obtain antiserum with marked
specificity for tumour-associated material
(Kelly & Levy, 1977). After a single
absorption with normal tissue insolubil-
ized by glutaraldehyde, and using a
quantitative complement-fixation test, this
antiserum showed virtually no reactivity
with normal tissue, and positive reactivity
with a bank of tumour extracts from
individual squamous-cell carcinomas, in-
dicating the presence of common HTAA
in lung cancer.
With the use of this antiserum, we
undertook to purify, or at least to enrich
for, material containing the antigenic
reactivity in the tumour extracts. By
using the antisera and the complement
fixation assay to monitor purification
steps, we were successful in purifying andDETECTION OF HTAA BY ELISA
characterizing the material as a component
with a mol. wt in the region of 70,000 and
an isoelectric point of about pH 8-5 (Kelly
& Levy, 1979). This antigenic component
of the tumour extract is considered to
constitute less than 0 5% of the starting
material.
We have realized that, if this isolated
component was to have significance in
developing techniques for the diagnosis or
prognosis of lung cancer, it would be
necessary to increase the sensitivity of our
assay. Even though the complement
fixation assay is quite sensitive, it is not as
sensitive as either radioimmunoassays
(RIA) or ELISAs (enzyme-linked immu-
nosorbent assays; Engvall & Carlsson,
1976). The ELISA has the advantages of
reagent stability, equal sensitivity to
RIA, and no problems ofisotope disposal,
and since we already had considerable
experience with this assay (Kelly et al.,
1979) we undertook to adapt our lung-
cancer studies to the ELISA. Since this
technique is extremely sensitive, it is
essential to have antisera with virtually
no reactivity with normal tissses, other-
wise background reactivities would oblit-
erate any specificity.
The present study reports on the effect
of normal sera, in comparison to
coded sera from patients subsequently
shown to have Stage 1 bronchogenic
carcinoma, and their ability to interfere
with the interaction of our specific anti-
tumour antibody, with our HTAA pre-
parations attached as asolid-phase antigen
to ELISA plates. In most cases, the serum
fromlung-cancerpatientsshowedamarked
ability to inhibit this interaction, whereas
the serum from normal individuals did not.
MATERIALS AND METHODS
Preparation ofantigenic material.-Extrac-
tion and purification of material from pools
of human lung tissue, one ofnormal lung and
the other of bronchogenic squamous-cell
carcinoma, were carried out according to
methods described by Kelly & Levy (1979).
Briefly, extractspreparedusing 3-0M KCIfrom
both normal and tumour tissue were subjected
to purification procedures which included
acid precipitation followed by salting out
with saturated (NH4)2SO4 to obtain a 33-
50%-saturation precipitable fraction. This
fraction was subsequently applied to DEAE
and fractionated using a 3-stage phosphate
buffer system. The tumour material eluting
from DEAE at the first stage with 0OO1M
phosphate was found to contain the major
antigenically active component. These result-
ing materials from DEAE are referred to as
C-lung I (from tumour tissue) and N-lung I
(from normal lung tissue) and are the anti-
genic materials used in the present study.
We should emphasize that this tumour frac-
tion, whilst being markedly enriched for the
HTAA, is not pure and contains at least 4
other major components of both normal and
tumour tissue (Kelly & Levy, 1979).
Preparation of antiserum.-Antigens pre-
pared as above, both C-lung I and N-lung I,
were passed over Sephadex G-200 (Pharma-
cia). Twenty mg of each DEAE Fraction I
in 2-0ml volumes were applied to a 500ml
column, equilibrated with borate-saline,
pH 7-5 at 4°C. Fractions of2-5 ml were collec-
ted and their absorbance was monitored at
280 nm in a Beckman DBG spectrophoto-
meter (Fig. 1). Individual fractions were then
applied to wells on an ELISA plate (see
below) at a concentration of 1.0 jug/ml in
pH 9-6 carbonate buffer in 0-2ml aliquots,
to monitor for the presence of the tumour-
specific component. The development ofthese
tests was carried out using previously pre-
pared antiserum (Kelly & Levy, 1979) that
was shown to be relatively specific for the
tumour antigen in the complement-fixation
test. Fraction 67 from the C-lung I elution
was found to be the most reactive in the
ELISA, in comparison to all other fractions
from either the C-lung I or N-lung I elutions.
Fraction 67 was used to immunize a rabbit
at a dosage of 10 ,ug/ml in 50% complete
Freund's adjuvant (CFA; Difco) at 3-week
intervals. The resulting antiserum was found
to be markedly enriched in tumour-specific
reactivity when tested in the ELISA with
preparations of C-lung-I and N-lung-I; how-
ever, it still contained antibodies which
reacted with normal lung tissue components
in the ELISA.
The antiserum described above was ab-
sorbed on a Sepharose 4B (Pharmacia)
cyanogen-bromide-linked immunoadsorbent
column containing serum from a pool of
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normal human sera. The procedure is
described by Porath et al. (1967). The anti-
serum afteradsorption showedlittlereactivity
with N-lung I material (even at high con-
centrations) while retaining good reactivity
with C-lung I material as monitored by the
ELISA (see Results). The antiserum thus pre-
pared is referred to as anti-C67. Normalrabbit
serum (NRS) was absorbed similarly on the
normal human serum adsorbent as a control.
Inordertoobservethespecificity ofthe anti
C67 antiserum, an ELISA titration was set up
with the adsorbed anti-C67 and adsorbed
NRS at dilutions of 1: 100, 1:200, 1:400
and 1:600 in phosphate-buffered saline
(PBS). Both sera were titrated with C-lung I
and N-lung I antigens at concentrations of
10 tg/ml. Anti-C67 serum was subsequently
used in the ELISA at a dilution of 1: 300.
Human serum samples.-Normal human
serum samples were obtained from the Cancer
Control Agency of British Columbia
(CCABC). Cancer patient and additional
normal sera were obtained as coded samples
from the Fred Hutchinson Cancer Research
Center in Seattle, Washington. These sera
were taken preoperatively from patients
subsequently found to have Stage I cancer of
the lung. A pool of normal sera was made up
of 20 individual normal serum samples. This
N-pool of serum was used as a reference
serum on every ELISA plate where patient
serum was being tested. These normal sera,
used in the pool, when tested individually
before pooling, all clustered in a limited range
with standard deviation of + 15%. They did
not interfere significantly with the basic test
when added at a dilution of 1: 20. There were
no exceptionally high normals in this group,
such as those seen in the CCABC samples
(Fig. 5, Panel 1).
ELISA.-The basic ELISA technique has
been described by Voller et al. (1976) and
Engvall & Carlsson (1976) and by ourselves
(Kelly et al., 1979). The assay which was used
throughout the present series of experiments
consisted of the attachment of 0-2 ml of
antigen (either C-lung I or N-lung I) at a
concentration of10 ,ug/ml inpH 9-6 carbonate
buffer to substrate microtitre plates (Cooke
Engineering Co., Alexandria, Va., No. 1 220
295) for 18 h at 4°C. The plates were washed
with PBS-Tween buffer, and sera to be tested
were added to the wells in 0-2ml aliquots and
incubated at room temperature for 2 h.
After washing with PBS-Tween, the develop-
ing antibody, alkaline phosphatase-linked
sheep anti-rabbit Ig (Voller et al., 1976) at a
dilution of 1:400 in PBS-Tween was added to
each well in a 0-2ml volume for another 2 h
incubation at room temperature. A final
washing with PBS-Tween was followed by the
addition of the enzyme substrate solution
(Sigma 104-105) in a volume of0-2 ml to each
well. The reaction was allowed to proceed
for 30 min, when the addition of 30M NaOH
(50 ,ul) to each well terminated the reaction.
The contents of each well were transferred
into tubes containing 0 75 ml distilled water
and read for adsorbence at 400 nm in a
Beckman DBG spectrophotometer. All tests
were run in triplicate. Standard deviations
forindividualsampleswerenever greater than
10%.
ELISA with human serum.-Patient and
normal human sera were prepared for the
ELISA in 2 ways. One involved each serum
sample being diluted in anti-C67 (1: 300) at
various dilutions and allowed to remain at
4°C overnight. These mixtures were then
applied to the antigen-coated microtitre wells
and the assay was continued as above. The
other method involved the dilution of each
serum sample in PBS-Tween (1:20). These
dilutions were maintained at 4°C overnight
and subsequently applied to the antigen-
coated wells. After a 2h incubation at room
temperature, the plates were washed as above
and anti-C67 antiserum (1: 300) was added to
each well for another 2h incubation. At this
time, enzyme-labelled sheep anti-rabbit Ig
(1: 400) was added and the assay was com-
pleted as described above.
In all experiments using the ELISA with
human serum, the absorbancy readings from
the triplicate tests on individual serum were
averaged and expressed as a percentage ofthe
readings ofthe wells on each plate containing
the equivalent dilution of the N-pool serum.
When N-pool serum was used at dilutions of
1: 20 or higher, it didnotdiffer markedlyfrom
the controls in which only the antigen and
anti-C67 were used.
RESULTS
Antiserum specificity
Preliminary experiments in this labora-
tory on identification oftumour-associated
antigens in lung-cancer tissue involved the
use of a quantitative complement-fixation
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assay (Kelly & Levy, 1977, 1979). It X
recognized that a more sensitive assay v
required if the significance of our findii
regarding these antigenic components a
human disease was to be investigated.
this end, the applicability of the ELI
technique was investigated. C-lung
material was applied to a Sephadex G-5
column and eluted with borate-saline
purify further the antigenically act
material in C-lung I. After monitoring 1
individual fractions eluting from 1
column by the ELISA, using an antiseri
(Kelly & Levy, 1979) shown to have
relatively good specificity for C-lung
in the complement-fixation assay (Ke
& Levy, 1979) it was found that Fracti
67 contained strong tumour-specific ar
genic activity. A similar elution with
lung I was carried out, and again fractic
were monitored for antigenic reactivi
The elution profiles and the individi
fractions showing tumour-specific ret
tivity are shown in Fig. 1. In Fig. 2, t
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FIG. 1. The elution profile of C-lung-I
(0 *) and N-pool-I (0 O) from
Sephadex G-200. The titration of indi-
vidual fractions in the ELISA are shown
(A A) as the net readings at 400 nm
for each ELISA test. Net levels were
obtained by subtracting those readings
found with the antiserum plus N-pool-I
fractions from readings obtained with the
C-lung I fractions.
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the FIG. 2.- ELISA readings for each fraction
eluting from Sephadex G-200 fractionation
of C-lung-I (U * *) and N-lung-I
(LII O I). Each fraction was attached to
ELISA plates in triplicate at a concentra-
tion of 1.0 ,ug/ml and subsequently tested
with rabbit antiserum directed to C-lung-I.
Readings are direct absorption measure-
ments at 400 nm. No correction was made
for NRS controls.
ELISA readings for each tube are shown.
It can be seen that, under the conditions
used here, there was considerable reac-
tivity in both the normal and tumour
material. However, the materials eluting
between Tubes 67 and 68 of the tumour-
extract fractionation showed much greater
reactivity than did the equivalent normal
tissue fractions, whereas greater reactivity
_ with normal material was observed be-
M tween Tubes 90-100. The intermediate
fractions appeared to be similar in their
reactivity with the antiserum.
Fraction C-67 was used with CFA to
immunize a rabbit. Serum was collected
from the animal and monitored by the
ELISA for the presence of specific anti-
bodies to C-lung I and N-lung I. It was
found that this antiserum, anti-C67, con-
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FIG. 3. Titration curves in ELISA using
absorbed anti-C67 or NRS with eitlher
C-lung-I or N-pool-I as the antigen at
10 jig/ml in the ELISA wells. *
anti-C67 with C-lung-I; A* -, ANRS
witl C-lung-I; 0 O, anti-C67 ith
N-pool-I; NRS wAith N-pool-1.
taine(1 an enriched population of tumour-
specific antibody, but at the same time
contained antibody which reacted with
material prepared from normal lung. By
passing this anti-C67 serum over an
immunoadsorbent column made by linking
serum from a pool ofnormal human sera to
cyanogen bromide-activated Sepharose
4B, anti-C67 was found to have lost
essentially all the anti-N-lung I reactivity,
while retaining reactivity with C-lung I.
Fig. 3 illustrates the titration curves from
an ELISA designed to establish the
specificity of anti-C67 serum. Anti-C67
was titrated with both C-lung I and N-
lung I at various dilutions, while at the
same time normal rabbit serum (NRS)
which had been absorded with the same
immunoadsorbent was similarly titrated.
The NRS did not react with either antigen,
whilst the anti-C67 titrated well with
C-lung I at all dilutions and gave essen-
tially background levels with the equiva-
lent preparation from normal lung tissue.
A diluLtion of anti-C67 of 1:300 was chosen
for subsequent testing as it afforded the
degree of specificity required for monitor-
ing human serum samples.
Hurnan serumi studies
Since the anti-C67 serutm exhibited
marked specificity in the ELISA with
tumour-derived material, tests were car-
ried out to determine whether the presence
of human sera (either from normal indi-
viduals or those with lung cancer) mixed
with the rabbit antiserum, influenced the
magnitude ofthe ELISA reaction. In order
to determine the effects of normal serum
on the ELISA with anti-C67 and C-lung-I
antigen, a series ofindividualnormalserum
samples were tested at dilutions of
1:10, 1: 20 and 1: 40, premixed with anti-
C67 for 18 h at 4°. These samples were
then tested in the ELISA and compared
to standard controls with no human serum
added. Representative results are shown
in Fig. 4. It can be seen that at 1:10 a
considerable proportion ofthe normal sera
tested did interfere markedly with the
test, whereas at 1:20 and 1:40 a majority
of the sera tested (1-6/24) fell within 10%
ofthe standard control (signified as 10000).
A pool of normal sera was subsequently
made from individual samples which ful-
filled this criterion and was used as a
standard at 1 :20 in following tests with
patients' sera.
A series of experiments were carried out
using coded preoperative patient and
normal sera obtained from the Fred
Hutchinson Cancer Research Center, along
with a large nuimber of normal sera
obtained from the CCABC. Individual
serum samples were set up in dilution
with anti-C67 (1:300) and applied to
C-lung I-coated microtitre wells. A pool
of normal sera, N-pool, was set up in a
similar manner and applied to every
ELISA plate as a reference serum for each
test. The results of these experiments at
a 1:20 dilution of patient serum in anti-
C67 are shown in Fig. 5. Each point
represents results from tests with indi-
vidual serum samples as a percentage of
the readings of tests with the N-pool
serum. The mean response for the 70
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FIG. 4.-The effect of individual serum
samples from normal individuals at various
diltutions on the development of ELISA
with C-lung-I and anti-C67. The absorbence
at 400 nm for the test ELISA with the
C-lung-I and anti-C67 were taken as 100%,
an(l results in the presence of normal
serum samples are presented as a percent-
age of that figure. Absorbence for the test
system varied between 0-800 and 1 100 at
400 nm from one plate to another. Per-
centages were always based on controls run
on the same plate as test samples.
normal sera obtained locally is indicated
on the first bar and averages at 120% ± 33
(s.d.) indicating that the reference N-pool
serum probably gave slightly lower results
in this ELISA than would a larger pool.
The second bar indicates the values
from serum samples obtained in the coded
series we received from Seattle, which
were subsequently found to have come
from normal individuals. They all fall
within the range of the normal response,
as do the 3 sera from patients with meta-
static malignant lung disease of non-
bronchogenic origin. The sera from the 3
categories of diseased patients (those with
subsequently diagnosed squamous, adeno-
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FicG. 5. Ability of various serum samples at
a dilution of 1: 20 to block the reaction of
anti-C67 with C-lung-I in the ELISA.
Horizontal lines indicate the mean for each
group. Results in all cases are shown as a
percentage of the ELISA reaction found
with a standard reference of a pool of
normal human serum. This standard was
run on every test plate in triplicate. All
samples tested, other than those shown in
the first bar diagram, constituted coded
sera obtained from the Fred Hutchinson
Cancer Research Center.
393
90
0
0-
.3
9
00
00
ir-
0
0 11
0 0
d% Oft- 0
0
* -
0. I
U*
|" .B. S. KELLY AND J. G. LEVY
alveolar or oat-cell carcinoma) segregated
outside the normal range, except for 3
adenocarcinoma sera which assayed at the
lower limits of the normal range. These
data indicated that patients with rela-
tively early bronchogenic malignancies
contain in their serum components which
inhibit the reactivity of our antiserum
(anti-C67) with the HTAA in our C-lung
I antigen preparations. These tests were
all run at least twice on separate days.
Very little deviation was found between
tests.
In order to follow the titration ofpatient
serum with anti-C67, a series of dilutions
for a representative number of sera from
benign or normal, squamous, adeno- and
oat-cell carcinoma patients were set up for
assay. Doubling dilutions ofpatient serum
were made in a 1:300 dilution of anti-C67
'14<
120
100
0
1:20 M40 1:80 1:160 1:320
DILUTIOPJ OF PATIENT SERUM
FIG. 6.-Titration of serum for its ability to
block the reaction of anti-C67 with
C-lung-I. Values are recorded as percent-
ages of ELISA values obtained using the
equivalent dilution of a normal serum
pool. Each line represents averaged results
from 3 individual sera tested + s.e.
A *, normal serum; 0 *, oat-
cell carcinoma patients' sera; 0 O,
squamous-cell carcinoma patient's sera;
A A, adenocarcinoma patients' sera.
All individual serum samples were taken
from those obtained from the Fred
Hutchinson Cancer Research Center.
and applied to microtitre wells containing
C-lung I. The averaged results for each
group ofsera are shown inFig. 6. Although
at the 1: 20 dilution there is a greater
differential between the normal sera and
the cancer patients' sera, significant dif-
ferences were maintained even at a dilu-
tion of 1: 80. The sera selected for these
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FIG. 7.-Ability of various serum samples at
a dilution of 1:20 to block the development
of background levels of colour in the
reaction of anti-C67 with N-lung-I in
ELISA. Result in all cases are shown as a
percentage of the ELISA reaction with a
standard reference ofpooled normal human
serum. *, serum from normal individuals;
0, serum from inidividuals with Stage I
bronchogenic carcinoma of various histo-
logical types. All test serum samples were
obtained from the Fred Hutchinson Cancer
Research Center. Cancer patients' sera were
selected from samples previously shown to
be representative of both weakly and
strongly suppressive samples in the specific
tests with anti-C67 and C-lung-I.
394DETECTION OF HTAA BY ELISA
1201
1001
0
0
2
0
0-o
801_
0
S.0
0
0
00
0
0
0
0
60'
FIG. 8.--The ability of various serum
samples at a dilution of 1: 20 to block the
subsequent reaction of anti-C67 witl
C-lung-I in ELISA. Sera were added to
ELISA plates to wlhich C-lung-I had been
attached and allow Ned to react for 2 h, after
which the specific antiserum was addedl.
0, serum from normal individuals; 0,
serum from individuals with Stage I
bronchogenic carcinoma of various histo-
logical types. All test sera were taken from
those obtained from the Fred Hutclhinson
Cancer Research Center. Cancer patients'
sera were selected to be representative of
those showing both hiigh and low levels of
blocking in previous tests.
titrations in each patient group were taken
from samples showing low, medium or
high inhibition ofthe normal reaction, and
therefore standard deviations as shown in
Fig. 6 demonstrate the upper limits for
such assays.
To test for the specificity of the in-
hibitory activity of these sera with C-lung
I, analogous tests were run using the
equivalent materials from normal lung
tissue (N-lung I). A number of sera, both
normal and from cancer patients, were
set up in a 1: 20 dilution with anti-C67
(1:300) and allowed to react with N-lung I
in the ELISA. Fig. 7 shows the results of
this assay. It can be seen that none of the
sera tested gave less than 9000 reactivity
of N-pool serum, indicating that there
was no inhibition ofthe reaction when the
normal material was used as the test
antigen. Because the anti-C67 reacts only
weakly and at levels comparable to those
seen with NRS with the N-lung I antigen
(i.e., background levels) we did not expect
to see any effect with the human serum.
However, if the patients' sera had con-
tained somenon-specificblockingelements,
it is conceivable that these background
levels might have been altered.
It was realized that the nature of the
assay did not preclude the possibility that
either tumour antigen or antibody in
patients' serum could effect such a result.
By virtue of the nature of the assay,
antigen in the patients' sera could effec-
tively remove the specific antiserum so
that it could no longer react with the solid-
phase antigen on the ELISA plate. It was
also clear that human antibody directed
toward the antigen on the ELISA plate
could also compete for the antigen with
the rabbit antiserum, and thus lower the
levels of the enzyme-labelled anti-rabbit
Ig detected in the assay.
In order to investigate the possibility
that cancer-patient serum contained anti-
body specific for C-lung I antigen, an
ELISA was set up with patients' sera at a
dilution of 1: 20 in PBS-Tween buffer.
These were allowed to react for 2 h with
the antigen (C-lung I) attached to wells in
microtitre, followed by the application of
anti-C67 (1:300) to the wells. The assay
was then exposed to the developing-
enzyme-labelled sheep anti-rabbit Ig fol-
lowed by substrate. The results of this
assay are shown in Fig. 8, in which it can
be seen that the sera from lung-cancer
patients effectively inhibited the subse-
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quent reaction of anti-C67 with the
antigen when compared to tests run with
sera from normal individuals. It is unlikely
that HTAA could be responsible for this
inhibition. Therefore, the possibility must
be considered that antibody in the serum
of patients may be responsible, in part,
for the inhibition found.
DISCUSSION
The ELISA has been shown to be both
a sensitive and an efficient method for
detecting antibodies to soluble antigens
(Kelly et al., 1979). In considering its
application in the present study, we were
cognizant of the problems of using an
assay with such marked sensitivity. Anti-
serum raised in this laboratory in rabbits
to a preparation ofprotein extracted from
human squamous-cell carcinoma was
shown to be tumour-specific in earlier
investigations using the complement-
fixation assay (Kelly & Levy, 1979). In
order to adapt our previous experimental
findings to a more sensitive assay (ELISA)
it was necessary to produce an antiserum
of high titre with marked tumour speci-
ficity and one that would give essentially
no reaction with equivalent material
isolated from normal lung tissue.
A Sephadex column was run with both
C-lung-I and N-lung-I preparations, and
each fraction collected was tested in
ELISA with our previously prepared anti-
serum. The results, shown in Figs. 1 and 2,
demonstrated that only one region of the
C-lung-I elution profile (Fractions 67-68)
produced significantly higher reactivity
in ELISA than did the equivalent N-
lung-I fractions, whereas materials eluting
between Tubes 90-100 from the N-lung-I
preparation showed considerably more
reactivity than the equivalent C-lung-I
fractions. Thus the antiserum used to
monitor the eluted fractions reacted with
both tumour and normal components. The
antiserum as used in the complement-
fixation assay appeared to be tumour-
specific (Kelly & Levy, 1979), However,
wThen used in the ELISA, it enabled us to
identify the fractions from the Sephadex
elutions that were most enriched for
tumour specificity. Antiserum raised to the
C-67 fraction demonstrated greater reac-
tivity to C-lung-I in the ELISA than it
did to N-lung-I, although it was not totally
specific before adsorption. However, after
passage ofthis antiserum over an immuno-
adsorbent column prepared with normal
human serum, it demonstrated almost
total specificity for the C-lung-I antigen in
ELISA (Fig. 3).
The apparent specificity of this system
in ELISA led us to investigate the possi-
bility that such an assay might be useful in
detecting HTAA in the serum of patients
with lung cancer. Preliminary studies with
serum from normal individuals demon-
strated that, though at a dilution of 1:10
serum could interfere with the assay, most
normal sera at a 1: 20 dilution did not
significantlv alter the results of the test
(Fig. 4). A pool of normal sera was pre-
pared from individual samples which did
not significantly alter the development of
ELISA at 1: 20. This was used as a stan-
dard in running subsequent tests with
serum from individuals with bronchogenic
carcinomas, as well as additional serum
samples from normal individuals. The
results of a survey, done with both known
normal sera (Fig. 5, Bar 1) and coded sera
(Fig. 5) indicated that the serum from
patients with early lung cancer was able
to inhibit the development of ELISA at a
dilution of 1: 20, whilst sera from normal
individuals did not. Some of the normal
sera tested at 1: 20 markedly enhanced
the colour development in ELISA (Fig.
5, Bar 1). The reasons for this are not yet
understood, although it has been suggested
that high-serum immunoglobulin levels
may accountfor it, since such results have
been seen by others and accounted for in
this way (Saunders, 1979). Further studies
on the dilution of human serum in anti-
C67 serum suggest the possibility of the
presence of titratable HTAA in the serum
of lung-cancer patients (Fig. 6). On sur-
veying a number ofhuman sera in mixture
with anti-C67 and using N-lung I as the
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reacting antigen, it was found that none
of the sera tested inhibited this reaction
(Fig. 7). This observation diminishes the
possibility that autoimmune reactions are
responsible for these results. As one would
expect, the degree of reactivity in this
system between normal antigen and anti-
body to tumour-specific components is
much less than that with tumour antigen
(Fig. 3).
The finding that the serum from lung-
cancer patients when allowed to react
with C-lung I antigen before reaction of
the antigen with the rabbit antiserum
(anti-C67)-could also effectively block
the reaction, indicated that these sera
might contain specific antibody as well as
antigen (Fig. 8).
In summary, these studies have permit-
ted us to develop a sensitive assay for
HTAA in human bronchogenic carcinoma,
and to demonstrate a component in the
serum of patients with preoperative Stage
I lung cancer which inhibits the reaction
of a purified rabbit antiserum with frac-
tionated HTAA of squamous-cell origin.
This kind of inhibition has not been seen
in any sera from normal individuals so far
tested at a dilution of 1: 20. Serum taken
from a few patients with chronic obstruc-
tive lung disease and tested in this system
in some cases showed marginal inhibitory
activity (data not shown) but were never
as inhibitory as the sera from the Stage I
patients. The usefulness of these observa-
tions, either prognostically or diagnostic-
ally, can only be evaluated after further
testing. The specificity of the reaction
observed here in respect of bronchogenic
carcinoma has not yet been ascertained,
and the testing of sera from patients with
other types of malignancy is part of a
continuing study in this laboratory. The
observation that patients with non-
bronchogenic metastatic disease in the
lung do not have inhibitory serum (Fig. 5)
may indicate that there is some specificity
in this test. However, other preliminary
studies indicate that there may well be
some cross-reactivity with some types of
malignancy (work in progress). It is clear
that a number of studies will have to be
done, using sera from carefully staged
patients, before these questions can be
answered satisfactorily.
The authors thank the following people for their
lhelp in supplying human serum for this study: Dr H.
Silver and Dr K. Karim, Cancer Control Agency of
British Columbia, Vancouver, B.C., Canada; Dr P.
Wright and Dr L. Hill, The Fred Hutchinson Cancer
Research Center, Seattle, Washington, U.S.A.; and
Dr W. Nelems, St Paul's Hospital, Vancouver, B.C.,
Canada. The authors also thank Dr Nelems for his
support and enthusiasm during the early phases of
this work, and Dr Ann Jackson for her help in pre-
paring the alkaline phosphatase conjugates.
This work was supported by Grant No. 6048 from
the National Cancer Institute of Canada.
REFERENCES
BRAATZ, J. A., McINTIRE, K. R., PRINCLER, G. L.,
KORTRIGHT, K. H. & HERBERMAN, R. B. (1978)
Purification and characterization of a human lung
tumor-associated antigen. J. Natl Cancer Inst., 61,
1035.
ENGVALL, E. & CARLSSON, H. E. (1976) Enzyme-
linked immunosorbent assay (ELISA). In First
International Symposium on Immunoenzymatic
Techniques. Ed. C. Feldman. Amsterdam: North-
Holland. p. 135.
KELLY, B. & LEVY, J. G. (1977) Evidence for a
common tumour-associated antigen in extracts of
human bronchogenic carcinoma. Br. J. Cancer,
35, 828.
KELLY, B. & LEVY, J. G. (1979) Purification of a
protein associated with human bronchogenic
squamous-cell carcinoma. Br. J. Cancer, 39, 224.
KELLY, B. S., LEVY, J. G. & SIKORA, L. (1979) The
use of the enzyme-linked immunosorbent assay
(ELISA) for the detection and quantification of
specific antibody from cell cultures. Immunology,
36, 989.
MOHR, J. A., NORDQUIST, R. E., RHOADES, E. R.,
COALSON, R. E. & COALSON, J. J. (1974) Alveolar
cell carcinoma-like antigen and antibodies in
patients with alveolar cell carcinoma and other
cancers. Cancer Res., 34, 904.
M6LLER, G. (1969) Immune responses by lympho-
cytes; their nature and regulation. In Immuno-
logical Tolerance. Eds. Landy & Braun. London:
Academic Press. p. 215.
PORATH, J., AXEN, R. & ERNBACK, S. (1969)
Chemical coupling of proteins to agarose. Nature,
215, 1491.
SAUNDERS, G. C. (1979) The art of solid phase
enzyme immunoassay including selectedprotocols.
In Immunoassays in the Clinical Laboratory. Ed.
R. M. Nakamura. New York: Alan Liss, Inc.
p. 99.
SEGA, E., NATALI, P. G., Ricci, C., MINEO, C. T. &
CITRO, J. (1974) Lung cancer tumour association
antigen: Isolated bygel filtration and characteriza-
tion by immunodiffusion. Int. Res. Communica-
tions System, 2, 1278.398 B. S. KELLY AND J. G. LEVY
VOLLER, A., BIDWELL, D. & BARTLETT, A. (1976)
Microplate enzyme iLmmunoassays for the im-
munodiagnosis of viral infections. In Manual of
Clinical Immunology. Eds. Rose & Freedman.
Am. Soc. Microbiol., Washington, D.C., p. 506.
WATSON, R. D., SMITH, A. G. & LEVY, J. G. (1975)
The detection of immunodiffusion of tumour
associated antigenic component in extracts of
human bronchogenic carcinoma. Br. J. Cancer, 32,
300.
YACHI, A., MATSURA, Y., CARPENTER, C. M. &
HYDE, L. (1968) Immunochemical studies on
human lung cancer antigen soluble in 50%
saturated ammonium sulfate. J. Natl Cancer Inst.,
40, 663.